Novavax Valuation
Is NVAX * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of NVAX * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: NVAX * (MX$69.07) is trading below our estimate of fair value (MX$794.66)
Significantly Below Fair Value: NVAX * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NVAX *?
Other financial metrics that can be useful for relative valuation.
What is NVAX *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$572.41m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 0.3x |
Enterprise Value/EBITDA | -0.6x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does NVAX *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 6.4x | ||
LAB B Genomma Lab Internacional. de | 0.9x | 8.0% | Mex$15.2b |
A086900 Medy-Tox | 4.2x | 18.0% | ₩921.4b |
688293 Shanghai OPM Biosciences | 17.4x | 39.0% | CN¥4.2b |
603387 Getein Biotech | 3.2x | n/a | CN¥4.7b |
NVAX * Novavax | 0.6x | 2.8% | Mex$572.4m |
Price-To-Sales vs Peers: NVAX * is good value based on its Price-To-Sales Ratio (0.6x) compared to the peer average (6.4x).
Price to Earnings Ratio vs Industry
How does NVAX *'s PE Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Sales vs Industry: NVAX * is good value based on its Price-To-Sales Ratio (0.6x) compared to the Global Biotechs industry average (10.8x).
Price to Sales Ratio vs Fair Ratio
What is NVAX *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 0.6x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate NVAX *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | Mex$69.07 | Mex$262.94 +280.7% | 81.2% | Mex$648.82 | Mex$68.30 | n/a | 5 |
Apr ’25 | Mex$80.00 | Mex$262.09 +227.6% | 81.2% | Mex$646.71 | Mex$68.07 | n/a | 5 |
Mar ’25 | Mex$91.30 | Mex$262.09 +187.1% | 81.2% | Mex$646.71 | Mex$68.07 | n/a | 5 |
Feb ’25 | Mex$71.50 | Mex$327.38 +357.9% | 73.3% | Mex$641.25 | Mex$67.50 | n/a | 5 |
Jan ’25 | Mex$81.41 | Mex$337.06 +314.0% | 71.5% | Mex$653.49 | Mex$85.99 | n/a | 5 |
Dec ’24 | Mex$94.15 | Mex$337.06 +258.0% | 71.5% | Mex$653.49 | Mex$85.99 | n/a | 5 |
Nov ’24 | Mex$125.00 | Mex$350.41 +180.3% | 65.0% | Mex$646.39 | Mex$85.05 | n/a | 5 |
Oct ’24 | Mex$127.70 | Mex$350.41 +174.4% | 65.0% | Mex$646.39 | Mex$85.05 | n/a | 5 |
Sep ’24 | Mex$138.00 | Mex$350.41 +153.9% | 65.0% | Mex$646.39 | Mex$85.05 | n/a | 5 |
Aug ’24 | Mex$147.00 | Mex$367.79 +150.2% | 60.7% | Mex$685.43 | Mex$150.46 | n/a | 5 |
Jul ’24 | Mex$130.00 | Mex$401.41 +208.8% | 54.0% | Mex$720.78 | Mex$158.22 | n/a | 6 |
Jun ’24 | Mex$140.00 | Mex$401.41 +186.7% | 54.0% | Mex$720.78 | Mex$158.22 | n/a | 6 |
May ’24 | Mex$138.00 | Mex$708.21 +413.2% | 95.6% | Mex$1,980.58 | Mex$180.05 | n/a | 6 |
Apr ’24 | Mex$122.00 | Mex$847.82 +594.9% | 75.7% | Mex$1,991.32 | Mex$181.03 | Mex$80.00 | 6 |
Mar ’24 | Mex$125.00 | Mex$847.82 +578.3% | 75.7% | Mex$1,991.32 | Mex$181.03 | Mex$91.30 | 6 |
Feb ’24 | Mex$205.97 | Mex$1,058.93 +414.1% | 62.3% | Mex$2,105.10 | Mex$248.78 | Mex$71.50 | 6 |
Jan ’24 | Mex$200.00 | Mex$1,198.49 +499.2% | 55.2% | Mex$2,143.64 | Mex$253.34 | Mex$81.41 | 6 |
Dec ’23 | Mex$325.00 | Mex$1,512.17 +365.3% | 80.5% | Mex$4,004.52 | Mex$309.53 | Mex$94.15 | 6 |
Nov ’23 | Mex$450.00 | Mex$1,631.39 +262.5% | 77.9% | Mex$4,152.03 | Mex$320.93 | Mex$125.00 | 6 |
Oct ’23 | Mex$371.00 | Mex$2,111.02 +469.0% | 61.9% | Mex$4,128.95 | Mex$398.93 | Mex$127.70 | 6 |
Sep ’23 | Mex$640.00 | Mex$2,916.66 +355.7% | 23.2% | Mex$4,192.70 | Mex$2,228.01 | Mex$138.00 | 5 |
Aug ’23 | Mex$1,109.00 | Mex$3,492.38 +214.9% | 15.8% | Mex$4,252.48 | Mex$2,711.73 | Mex$147.00 | 5 |
Jul ’23 | Mex$1,151.50 | Mex$3,458.47 +200.3% | 15.8% | Mex$4,162.23 | Mex$2,654.18 | Mex$130.00 | 5 |
Jun ’23 | Mex$1,072.60 | Mex$3,472.59 +223.8% | 14.7% | Mex$4,111.50 | Mex$2,621.82 | Mex$140.00 | 6 |
May ’23 | Mex$920.15 | Mex$3,773.51 +310.1% | 9.9% | Mex$4,180.82 | Mex$3,029.58 | Mex$138.00 | 6 |
Apr ’23 | Mex$1,485.88 | Mex$4,048.69 +172.5% | 15.3% | Mex$5,164.15 | Mex$3,098.49 | Mex$122.00 | 6 |
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.